Trial · NCT03523728
Results by group384
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 384
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | Stage 1- Placebo | 6.35 | 95% Confidence Interval 5.10 to 7.62 | percent change in TKV/year | |
| Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | Stage 1- Venglustat 8 mg | 7.71 | 95% Confidence Interval 6.46 to 8.98 | percent change in TKV/year | |
| Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | Stage 1- Venglustat 15 mg | 6.38 | 95% Confidence Interval 5.11 to 7.66 | percent change in TKV/year | |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | Placebo | -2.40 | 95% Confidence Interval -3.30 to -1.49 | mL/min/1.73 m^2/year | |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | Venglustat 8 mg | -4.82 | 95% Confidence Interval -5.82 to -3.83 | mL/min/1.73 m^2/year | |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | Venglustat 15 mg | -4.89 | 95% Confidence Interval -5.80 to -3.99 | mL/min/1.73 m^2/year | |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | Stage 1- Placebo | -3.14 | 95% Confidence Interval -4.09 to -2.18 | mL/min/1.73 m^2/year | |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | Stage 1- Venglustat 8 mg | -4.74 | 95% Confidence Interval -5.68 to -3.80 | mL/min/1.73 m^2/year | |
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | Stage 1- Venglustat 15 mg | -4.59 | 95% Confidence Interval -5.53 to -3.65 | mL/min/1.73 m^2/year | |
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | Stage 1- Placebo | -0.09 | Standard Error 0.15 | score on a scale | |
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | Stage 1- Venglustat 8 mg | 0.01 | Standard Error 0.17 | score on a scale | |
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | Stage 1- Venglustat 15 mg | -0.35 | Standard Error 0.16 | score on a scale | |
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | Placebo | -0.20 | Standard Error 0.23 | score on a scale | |
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | Venglustat 8 mg | -0.31 | Standard Error 0.36 | score on a scale | |
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | Venglustat 15 mg | -0.36 | Standard Error 0.23 | score on a scale | |
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | Stage 1- Placebo | -0.26 | Standard Error 0.23 | score on a scale | |
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | Stage 1- Venglustat 8 mg | -0.10 | Standard Error 0.25 | score on a scale | |
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | Stage I- Venglustat 15 mg | -0.64 | Standard Error 0.24 | score on a scale | |
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | Placebo | 0.02 | Standard Error 0.38 | score on a scale | |
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | Venglustat 8 mg | -0.85 | Standard Error 0.55 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03523728/results